Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment

Trial Profile

Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Acronyms STEP
  • Most Recent Events

    • 09 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 30 Jan 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top